Sema4 and BioSymetrics Partner for Data-Driven Drug Discovery to Advance Precision Medicine | News
STAMFORD, Connecticut and BOSTON and TORONTO, Feb. 2022 (GLOBE NEWSWIRE) — Sema4 (Nasdaq: SMFR), an AI-driven genomics and clinical data intelligence platform company, and BioSymmetry, a phenomics-driven drug discovery company, today announced a strategic partnership to accelerate the development of new drugs for patients and pharmaceutical companies. The partnership will leverage Centrellis®, Sema4’s proprietary medical intelligence platform, and Elion, BioSymetrics’ phenotypic drug discovery platform, to discover new treatments, initially in cardiovascular, rare and neurological diseases. Together, the companies will launch up to 10 new therapeutic programs in areas of high unmet need and where multi-omics offers a differentiated approach to drug discovery.
“We are excited to work closely with BioSymetrics to discover drug candidates of greater value and without risk to patients,” said Eric Schadt, PhD, Founder and CEO, Sema4. “The power of applying our predictive network modeling to drug discovery will result in greater success, decreased attrition, and a deeper understanding of the patient journey as it relates to identifying treatments. Our partnership with BioSymetrics also aligns with our goal of collaborating with biopharmaceutical companies to drive innovation throughout the drug lifecycle, enabling the development of next-generation precision medicine therapies.
Together, Sema4 and BioSymetrics will provide a novel and differentiated approach to drug discovery to produce more effective drug candidates. The two companies plan to improve the translational success of new medicines by combining the power of Centrellis, one of the largest and fastest growing integrated health information platforms that includes approximately 12 million clinical records. anonymized, with BioSymetrics’ AI-driven approach to leveraging clinical data for use in a phenotype-driven therapeutic discovery process. Co-founded by Anthony Iacovone, a serial entrepreneur with a proven track record in leading AI and machine learning companies, and Gabriel Musso, PhD, a scientific leader in applying AI to biomedicine, BioSymetrics has established itself in the life sciences industry under the leadership of a team of experienced biopharmaceutical and technology executives, and through its partnerships with top healthcare systems and pharmaceutical companies.
Sema4 and BioSymetrics will combine patient genomic data, innovative AI solutions and phenomics to better translate data into discoveries. They will begin their partnership by exploring the discovery of therapeutic potential for atherosclerosis, a slow, progressive disease characterized by hardening or narrowing of the arteries that can lead to heart attack or stroke. Subsequently, they will launch three other therapeutic programs focusing on rare diseases before finalizing the remaining programs.
“Connecting the dots between human clinical and genomic data and experimental model systems, using advanced machine learning, increases the likelihood of successfully advancing new drugs that work well for more patients,” said Anthony Iacovone. , co-founder and CEO of BioSymetrics. “Sema4 has unique access to multi-omics data and insights that together will improve our ability to find treatment for different groups of people living with diseases where there is currently no treatment or standard of care. is weak.”
Sema4 is a patient-centric health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 transforms healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and define optimal, individualized health trajectories. Centrellis®, our innovative health intelligence platform, enables us to generate a more comprehensive understanding of disease and well-being and provide science-based solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners and data should be shared for the benefit of all.
BioSymetrics is a phenomics-driven drug discovery company whose vision is to translate data into discovery. BioSymetrics integrates clinical and experimental data, using machine learning, to translate the biology of human disease and advance precision medicines. Company partners with a diverse network of life science and health system partners, including Janssen, Northwell Health and Sema4, for end-to-end drug discovery, from clinical strategy to genetic disease prioritization to small molecule screening and mechanism of action. BioSymetrics is a remote business with groups of people in Boston, Toronto, and California, and we’re hiring. For more information, please visit www.biosymetrics.com.
Radley Moss, Senior Director of Communications, Sema4, [email protected]
Amanda Guisbond, Vice President of Marketing and Experience, BioSymetrics, [email protected]
A video accompanying this press release is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/4e3094e9-d709-4fa2-b9b0-b37a61423327
Copyright 2022 GlobeNewswire, Inc.